Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesThe similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients
Journal of Cancer Research & Clinical Oncology, 10/01/09
Kim HR et al. – Pemetrexed has comparable survival benefits in NSCLC patients that show objective response or stable disease
Methods- Retrospectively reviewed medical records
- Patients with histologically proven stage IIIB or IV NSCLC
- Treated with pemetrexed after failure of prior chemotherapy
- Objective response rate for 99 enrolled patients was 13.1% and 22 patients achieved stable disease (SD)—a disease control rate of 35.4%
- Progression-free survival and overall survival (OS) were 1.8 months and 7.6 months
- Patients who achieved SD and pemetrexed-responders showed similar OSs
- Squamous cell carcinoma histology showed no significant OS difference between those that achieved disease control or progression
- Subgroup analysis of OS revealed histology and response to first-line therapy predicted response to pemetrexed
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Parathyroid hormone-related peptide and parathyroid hormone-related peptide receptor type 1 expression in human lung adenocarcinoma
Chest, 12/16/09
Inhalation exposure to ambient polycyclic aromatic hydrocarbons and lung cancer risk of Chinese population
Proceedings of the National Academy of Sciences of the United States of America, 12/16/09
A Small Step Towards Personalized Medicine for Non-small Cell Lung Cancer
Discovery Medicine, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor